Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Vertex Pharmaceuticals

Vertex Pharmaceuticals

Vertex Pharmaceuticals discovers, develops and commercializes pharmaceutical products for treatment of cystic fibrosis, cancer, inflammatory bowel, autoimmune disease and neurological disorders.

Vertex Pharmaceuticals discovers, develops and commercializes pharmaceutical products for treatment of cystic fibrosis, cancer, inflammatory bowel, autoimmune disease and neurological disorders. Vertex’s product Trikafta was approved by the USFDA in 2019 for treatment of cystic fibrosis. Other approved cystic fibrosis medicines from Vertex include Symdeko, Orkambi and Kalydeco.

Vertex and CRISPR Therapeutics are collaborating with their treatment, CTX001, made from a patient’s own stem cells harvested and edited using CRISPR technology to increase fetal hemoglobin levels to treat transfusion-dependent beta thalassemia and sickle cell disease.

Timeline

Products

Patents

Further Resources

Title
Author
Link
Type
Date

Prioritizing Personal & Professional Development

Web

January 26, 2022

The History and Future of Vertex Pharmaceuticals

Web

May 14, 2021

News

Title
Author
Date
Publisher
Description
FinSMEs
September 9, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
DelveInsight Business Research, LLP
June 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- DelveInsight's Chronic Obstructive Pulmonary Disease (COPD) Market report puts forward a detailed perspective on epidemiology, current...
Alex Keown
June 11, 2021
BioSpace
Shares of Vertex fell more than 13% in premarket trading after it announced that it will not advance a novel small molecule corrector of the Z-AAT protein into a Phase III study.
Amirah Al Idrus
April 22, 2021
FierceBiotech
Vertex Pharmaceuticals is inking another gene-editing deal, days after retooling a partnership with CRISPR Therapeutics to the tune of $900 million. This time, the company is teaming up with Obsidian Therapeutics to discover new gene-editing treatments that can be controlled with small molecules.
Mark Terry
April 20, 2021
BioSpace
Under the terms of the expanded deal, Vertex will be responsible for 60% of the costs of developing, manufacturing and commercializing CTX001 with support from CRISPR Therapeutics, and will receive 60% of profits from global sales.
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.